Imunossupressor leflunomide anodic behaviour at a boron-doped diamond electrode

Goldenberg, 1999, Clin. Ther., 21, 1837, 10.1016/S0149-2918(00)86732-6 Bertolini, 1997, J. Med. Chem., 40, 2011, 10.1021/jm970039n Rozman, 2002, Clin. Pharmacokinet., 41, 421, 10.2165/00003088-200241060-00003 FDA. Study YU#204. Clinical pharmacology/biopharmaceutics review. AravaLeflunomide tablets; summary basis of approval equivalent. FDA Summary Basis of Approval. NDA: 20–905, 1998. Weinblatt, 1999, Arthritis Rheum., 42, 1322, 10.1002/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P Breedveld, 2000, Ann. Rheum. Dis, 59, 841, 10.1136/ard.59.11.841 Osiri, 2003, J. Rheumatol., 30, 1182 Geborek, 2002, Ann. Rheum. Dis., 61, 793, 10.1136/ard.61.9.793 J.S. Smolen, J.R. Kalden, D.L. Scott, B. Rozman, T.K. Kvien, A. Larsen, I. Loew-Friedrich, C. Oed, R. Rosenburg, and the European Leflunomide Study Group∗, Lancet, vol. 353, 1999, pp. 259–266. Kremer, 2004, J. Rheumathol., 31, 1521 Aletaha, 2003, Ann. Rheum. Dis., 62, 944, 10.1136/ard.62.10.944 Christopherson, 2002, Acc. Chem. Res., 35, 961, 10.1021/ar0000509 Herrmann, 2000, Immunopharmacology, 47, 273, 10.1016/S0162-3109(00)00191-0 van Roon, 2004, 36, 17 Yeniceli, 2006, J. Pharmaceut. Biomed., 40, 197, 10.1016/j.jpba.2005.06.030 Chan, 2004, J. Chromatogr. B, 803, 331, 10.1016/j.jchromb.2004.01.016 Schmidt, 2003, Biomed. Chromatogr., 17, 276, 10.1002/bmc.244 Parekha, 2010, J. Chromatogr. B, 878, 2217, 10.1016/j.jchromb.2010.06.028 Enache, 2009, Electrochem. Commun., 11, 1342, 10.1016/j.elecom.2009.04.017 Hollas, 2004 Pavia, 2001 Salaar-Banda, 2006, Electrochim. Acta, 51, 4612, 10.1016/j.electacta.2005.12.039 Brett, 1993 products.sanofi.ca/en/arava.pdf, (accessed 31.01.2014). Lund, 2001